NOVALIQ GmbH
- Country
- 🇩🇪Germany
- Ownership
- Holding
- Established
- 2007-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.novaliq.de
A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine
- Conditions
- Dry Eye Disease
- Interventions
- Drug: Saline solution, 0.6%
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Novaliq GmbH
- Target Recruit Count
- 204
- Registration Number
- NCT06329661
- Locations
- 🇺🇸
CYS-007 Investigational Site, Memphis, Tennessee, United States
ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
- Conditions
- Dry Eye Disease
- Interventions
- Drug: CyclASol topical ocular, eye dropsDrug: Vehicle topical ocular, eye drops
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Novaliq GmbH
- Target Recruit Count
- 834
- Registration Number
- NCT04523129
- Locations
- 🇺🇸
CYS-004 Investigational site, Ogden, Utah, United States
🇺🇸CYS-004 Investigational Site, Seattle, Washington, United States
🇺🇸CYS-004 Investigation Site, Kansas City, Missouri, United States
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004
- Conditions
- Dry Eye Disease (DED)
- Interventions
- Drug: CyclASol Ophthalmic Solution
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Novaliq GmbH
- Target Recruit Count
- 202
- Registration Number
- NCT04523142
- Locations
- 🇺🇸
CYS-005 Investigtional Site, Raynham, Massachusetts, United States
🇺🇸CYS-005 Investigational Site, Lynchburg, Virginia, United States
Safety and Efficacy of NovaTears® + Omega-3 (0.2%) Eye Drops on Signs and Symptoms of Dry Eye
- Conditions
- Evaporative Dry Eye Disease
- Interventions
- Device: NovaTears® + Omega-3 (Perfluorohexyloctane with 0.2% w/w Omega-3 fatty acid ethyl esters)
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2021-04-15
- Lead Sponsor
- Novaliq GmbH
- Target Recruit Count
- 36
- Registration Number
- NCT04521465
- Locations
- 🇩🇪
NTO-001 Investigational Site, Nürnberg, Germany
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- Novaliq GmbH
- Target Recruit Count
- 336
- Registration Number
- NCT03333057
- Locations
- 🇺🇸
Investigational site, Jacksonville, Florida, United States
🇺🇸Investigational Site, Nashville, Tennessee, United States
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
- Conditions
- Dry Eye Disease
- Interventions
- Drug: Vehicle topical ocular, eye dropsDrug: CyclASol topical ocular, eye drops
- First Posted Date
- 2017-09-26
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Novaliq GmbH
- Target Recruit Count
- 328
- Registration Number
- NCT03292809
- Locations
- 🇺🇸
CYS-003 Investigational Site, Norfolk, Virginia, United States
Influence of Perfluorohexyloctane (NovaTears) on Tear Film Thickness in Patients With Mild to Moderate Dry Eye Disease
- Conditions
- Dry Eye Disease
- Interventions
- Device: NovaTears®Device: Hydrabak®
- First Posted Date
- 2017-02-09
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- Novaliq GmbH
- Target Recruit Count
- 48
- Registration Number
- NCT03048526
- Locations
- 🇦🇹
Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria
CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2019-11-06
- Lead Sponsor
- Novaliq GmbH
- Target Recruit Count
- 207
- Registration Number
- NCT02617667
- Locations
- 🇺🇸
CYS-002 Investigational Site, Quincy, Massachusetts, United States
NovaTears® Eye Drops Observational Study NT-002
- Conditions
- Dry Eye Syndromes
- Interventions
- Device: NovaTears® Eye Drops
- First Posted Date
- 2015-02-05
- Last Posted Date
- 2016-03-09
- Lead Sponsor
- Novaliq GmbH
- Target Recruit Count
- 72
- Registration Number
- NCT02356341
- Locations
- 🇩🇪
Prof. Dr. Norbert Schrage, Cologne, Germany
🇩🇪University Eye Hospital of the FAU Erlangen-Nuremberg, Erlangen, Germany
🇩🇪University Eye Hospital Heidelberg, Heidelberg, Germany
NovaTears® Eye Drops Observational Study NT-003
- Conditions
- Dry Eye Syndromes
- Interventions
- Device: NovaTears® Eye Drops
- First Posted Date
- 2015-02-05
- Last Posted Date
- 2016-03-09
- Lead Sponsor
- Novaliq GmbH
- Target Recruit Count
- 25
- Registration Number
- NCT02356328
- Locations
- 🇩🇪
University Eye Hospital Freiburg, Freiburg, Germany
🇩🇪Department of Ophthalmology, University of Cologne, Cologne, Germany